Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xerava (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China
Details : XERAVA® (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xerava (eravacycline) is bacteriostatic which disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : TTY BIOPHARM CO LTD
Deal Size : Undisclosed
Deal Type : Partnership
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava in Taiwan
Details : Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug res...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : TTY BIOPHARM CO LTD
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired MDR and are pr...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and a...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2021
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.
Product Name : TP-434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Melinta Therapeutics
Deal Size : $55.0 million
Deal Type : Merger
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
Details : Through this acquisition, Melinta will enhance its commercial portfolio with XERAVATM. Once the transaction closes, Melinta will have a portfolio of five complementary marketed antibiotics: VABOMERE, ORBACTIV, BAXDELA, MINOCIN for Injection, and XERAVATM...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : $55.0 million
September 06, 2020
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Melinta Therapeutics
Deal Size : $55.0 million
Deal Type : Merger